About the journal
Targeted Oncology is a journal published by Adis, Springer Healthcare in France. It is listed in MEDLINE according to the sources read. Declared publication charge: 4,390 EUR. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Adis, Springer Healthcare
- ISSN
- 1776-2596 · 1776-260X
- Country
- France
- Access
- Not open access / not declared
- Declared publication charge
- 4,390 EUR
- Declared peer-review model
- peer_review
- Official website
- https://www.springer.com/journal/11523
Index listings
- MEDLINE · 2009-01-01
- Indexing
- MEDLINE
- APC
- 4,390 EUR
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 100 days received→accepted — computed from PubMed (n=78)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
1222
Last recorded publication year
2026
h-index
72
i10-index
663
From OpenAlex open data (CC0).
Editorial & policy6
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 95%
- ORCID iDs in current deposits
- 78%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101270595
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Research Studies
- Lung Cancer Research Studies
Show all subjects (50)
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Renal cell carcinoma treatment
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- Advanced Breast Cancer Therapies
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatocellular Carcinoma Treatment and Prognosis
- Prostate Cancer Treatment and Research
- Prostate Cancer Treatment and Research
- PI3K/AKT/mTOR signaling in cancer
- PI3K/AKT/mTOR signaling in cancer
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- Melanoma and MAPK Pathways
- Melanoma and MAPK Pathways
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- PARP inhibition in cancer therapy
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Monoclonal and Polyclonal Antibodies Research
- Monoclonal and Polyclonal Antibodies Research
- Multiple Myeloma Research and Treatments
- Multiple Myeloma Research and Treatments
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Neuroendocrine Tumor Research Advances
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Bladder and Urothelial Cancer Treatments
- Bladder and Urothelial Cancer Treatments
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ